Taro Pharmaceutical Industries Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Taro Pharmaceutical Industries Ltd. generated cash of $132,388,000, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore $208,414,000.
Cash Flow
| 2015 | 406.78M | -92.08M | -10.91M |
|---|---|---|---|
| 2016 | 395.12M | -284.73M | -15.33M |
| 2017 | 437.53M | -117.77M | -294.89M |
| 2018 | 323.68M | -241.63M | -106.98M |
| 2019 | 323.70M | 257.13M | -588.84M |
| 2020 | 271.60M | -298.16M | -26.98M |
| 2021 | 45.77M | 67.74M | -24.19M |
| 2022 | -158.69M | -170.58M | -24.93M |
| 2023 | 31.75M | -125.55M | 0 |
| 2024 | 132.38M | 84.34M | 0 |
TARO Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 154.49M | 251.13M | 605.17M | 513.35M | 567.45M | 576.61M | 600.39M | 576.75M | 481.64M | 209.96M |
Operating activities | ||||||||||
Net income | 53.86M | 25.44M | 58.26M | -400.74M | 244.55M | 282.12M | 210.07M | 456.66M | 541.27M | 484.83M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 31.09M | 32.12M | 25.91M | 23.68M | 21.38M | 18.59M | 16.49M | 14.82M | 14.84M | 15.79M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 40.21M | 37.48M | -6.22M | 21.68M | 2.72M | -32.08M | -2.29M | 34.41M | -16.38M | -85.27M |
Inventories | 21.72M | -16.92M | -2.08M | -27.21M | -4.99M | -5.51M | -1.97M | -3.77M | -19.01M | -7.02M |
Accounts payable | -33.83M | 1.64M | -2.12M | 32.30M | -6.20M | 9.88M | 9.04M | -2.29M | -679K | -542K |
Cash generated by operating activities | 132.38M | 31.75M | -158.69M | 45.77M | 271.60M | 323.70M | 323.68M | 437.53M | 395.12M | 406.78M |
Investing activities | ||||||||||
Purchases Of Investments | -1.5M | -107.70M | -66.67M | -1.13B | -269.76M | -8.36M | -770.49M | -286.63M | -300.82M | -43.34M |
Investments In Property Plant And Equipment | -54.21M | -17.84M | -12.03M | -17.14M | -28.39M | -30.68M | -29.53M | -35.75M | -19.10M | -19.93M |
Acquisitions Net | 0 | -1.97M | -91.87M | 161K | 0 | 3.66M | 2.65M | 8.43M | -166K | 59K |
Cash generated by investing activities | 84.34M | -125.55M | -170.58M | 67.74M | -298.16M | 257.13M | -241.63M | -117.77M | -284.73M | -92.08M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -24.93M | -24.19M | -26.98M | -88.84M | -106.98M | -294.89M | -9.45M | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.88M | 0 |
Cash used in financing activities | 0 | 0 | -24.93M | -24.19M | -26.98M | -588.84M | -106.98M | -294.89M | -15.33M | -10.91M |
Net Change In Cash | 208.41M | -96.63M | -354.04M | 91.82M | -54.09M | -9.16M | -23.78M | 23.64M | 95.11M | 271.67M |
Cash at end of period | 362.90M | 154.49M | 251.13M | 605.17M | 513.35M | 567.45M | 576.61M | 600.39M | 576.75M | 481.64M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |